Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

CAPS Rating: 1 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases

Results 1 - 16 of 16

Recs

1
Member Avatar rcwcfa (< 20) Submitted: 6/11/2014 8:53:45 PM : Underperform Start Price: $7.25 ACHN Score: +0.78

The company's entire net worth is due to last year's financing. The company will continue to lose cash and financial flexibility unless it gets bought out. Given the performance recently, I expect the stock to drop back down to $4.

Recs

0
Member Avatar genedom (97.36) Submitted: 3/11/2014 11:43:12 PM : Underperform Start Price: $3.15 ACHN Score: -125.39

No future

Recs

2
Member Avatar HarHarMahadev (< 20) Submitted: 2/4/2014 12:02:15 PM : Outperform Start Price: $3.33 ACHN Score: +106.35

Lot of Institutional buying recently..

Recs

0
Member Avatar Haugurafpeningum (52.62) Submitted: 1/25/2014 4:14:28 PM : Outperform Start Price: $3.66 ACHN Score: +88.90

porte3 bottom of a rising trendchannel

Recs

1
Member Avatar whoodatstockhot (89.20) Submitted: 9/30/2013 12:50:22 PM : Outperform Start Price: $2.94 ACHN Score: +130.43

One of the best buying opportunites I've seen all year. Stonrg pipeline of hepatitis C medicines in its portfolio.

Recs

1
Member Avatar fatmoneyrz (96.53) Submitted: 9/30/2013 9:47:42 AM : Outperform Start Price: $3.50 ACHN Score: +90.49

This is a best in breed, but volatile one, which should head right back up. Take advantage of the sell offs

Recs

1
Member Avatar TerryHoodSr (48.28) Submitted: 7/31/2013 3:46:45 PM : Outperform Start Price: $6.37 ACHN Score: -2.11

potential

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:10:16 PM : Underperform Start Price: $7.18 ACHN Score: +14.62

Short. Biopharma. Big insider selling. 6000x P/S . Last 3 years cash flow from selling stock: 44M, 61M, 72M. (Much more than investing activities).

Recs

0
Member Avatar Fishbolb (60.11) Submitted: 10/16/2012 6:42:19 PM : Underperform Start Price: $10.78 ACHN Score: +67.72

Late to the Hep C game.

Recs

1
Member Avatar getrichslowfool (< 20) Submitted: 1/13/2012 3:21:38 PM : Outperform Start Price: $12.32 ACHN Score: -93.86

Yeah it's run up a bunch recently, but I think IDIX will get bought out and this will run up more with it. Time will tell

Recs

1
Member Avatar jamescraigjones (< 20) Submitted: 10/19/2011 10:43:10 AM : Outperform Start Price: $6.22 ACHN Score: -43.30

It is clear to see that the Hep C market will be exploding in the next year to 3 years as developers continue to improve on the technology and pipelines. Regardless of how the sector or the overall market is performing, you cant ignore the kind of money that this market will tap into.

Recs

0
Member Avatar EclecticRecluse (79.59) Submitted: 5/25/2011 10:01:35 AM : Underperform Start Price: $5.87 ACHN Score: +24.99

Low Sales and Return on Equity

Recs

0
Member Avatar THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:24:28 AM : Underperform Start Price: $5.99 ACHN Score: +37.10

Shorting a bunch of biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

Recs

0
Member Avatar poorbastard2011 (< 20) Submitted: 1/14/2011 7:04:28 AM : Outperform Start Price: $5.04 ACHN Score: -9.22

Long Term Bullish Breakout
Short Term Upward Sloping Trading Channel
Short Term Bullish Breakout

Recs

0
Member Avatar NetscribePhrmtcl (97.38) Submitted: 3/20/2007 8:42:53 AM : Underperform Start Price: $7.06 ACHN Score: +39.69

Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the company concentrates on the development of antivirals and antibacterials. It is targeting the antiviral development efforts on treatments for HIV infection and chronic hepatitis C, and is directing its antibacterial development efforts toward treatments for serious hospital-based bacterial infections.

Its two lead drug candidates are Elvucitabine, which is in the Phase II clinical trials in HIV-infected patients, and ACH-806, which the company is evaluating in collaboration with Gilead Sciences in a Phase I clinical trial for the treatment of chronic hepatitis C. The company is also evaluating its third drug candidate, ACH-702, in late-stage, pre-clinical studies for the treatment of serious hospital-based bacterial infections.

Revenues witnessed a sharp 91% decline for the quarter ended September 2006. The decrease in 2006 is the result of a reduction in milestone payments under collaboration with Gilead Sciences. Net loss applicable to common shareholders increased 71%, reflecting a sharp increase in R&D expenses and administrative costs. The company has incurred losses of $100 million from inception to September 2006 and had an accumulated deficit of $113.6 million through September 30, 2006.

Achillion appears to be a weak investment proposition based on the delay in the expected development timeline for the HIV & HCV program. The launch of a replicase inhibitor for HCV is expected to be in 2011, rather than 2010, which would hamper the company’s near term earning prospects.

Recs

0
Member Avatar turingmouse (42.44) Submitted: 2/12/2007 2:05:24 AM : Outperform Start Price: $9.22 ACHN Score: -66.29

took to much of a beating on hep-c trial news. should outperform.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement